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Acetylcholine is a fast‑acting neurotransmitter in synapses and neuromuscular junctions that is decreased in Alzheimer’s 
disease (AD) by hyper‑activation of acetylcholinesterase (AChE), which leads to progressive loss of memory and neurobehavioral 
abnormalities. Therefore, AChE inhibitors have therapeutic potential in AD that could include natural compounds such as bile 
acids. Bile acids, as potent molecules, could improve some types of neurodegenerative diseases via antioxidant effects and other 
unknown mechanisms. The aim of this study was to investigate beneficial effects of bile acids on AChE catalytic and non‑catalytic 
functions, amyloid plaque deposit and memory in a rat model of AD. The effects of sodium deoxycholate and cholic acid on AChE 
activity were assessed by in vitro assay. Then, the bile acids’ potential therapeutic effects were investigated on nucleus basalis 
of Meynert lesioned rats using behavioral evaluation, biochemical tests and histological methods. Molecular docking simulation 
was also implemented to investigate the possible interaction between bile acids and AChE. According to the in vitro and in vivo 
results, sodium deoxycholate could efficiently inhibit the catalytic function of the enzyme by interacting with the catalytic site, 
while cholic acid interacted with the peripheral anionic site and inhibited chaperone activity of the enzyme that led to the reduced 
amyloid plaque deposition. The co‑administration of cholic acid and sodium deoxycholate showed these compounds are able to 
simultaneously inhibit the catalytic and non‑catalytic functions of the enzyme. This study clarifies the roles of natural bile acids in 
the nervous system and in AChE function through multiple experimental and simulation methods. 
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive dementia, 
hallmarked by amyloid plaque deposition and charac‑
terized by memory loss and cognitive dysfunction (Dong 
et al., 2012). Cumulative evidence strongly supports 
that decreased acetylcholine (ACh) neurotransmitter, as 
a result of acetylcholinesterase (AChE) hyperactivation, 
plays an important role in the occurrence and develop‑
ment of neurological disorders related to AD in patients 
and animal models (Anand and Singh, 2013). Therefore, 
AChE inhibition by various drugs, such as donepezil, ri‑
vastigmine and galantamine, are used to improve symp‑
toms of AD pathophysiology (Anand and Singh, 2013). 
AChE which belongs to the α/β hydrolase fold family is 
an ACh‑hydrolyzing enzyme in the synapse and neuro‑
muscular junction that terminates cholinergic impulses 
in nerves (Holmquist, 2000). Despite the catalytic activ‑
ity, AChE participates in multiple biological functions, 
such as neuronal cell differentiation, dendrite and axon 
formation, cell adhesion and neurodegeneration in Alz‑
heimer’s disease (Dong et al., 2004). Two sites of ligand 
interaction contribute to the catalytic and non‑cata‑
lytic functions of AChE: a catalytic active site (CAS) at 
the bottom of a deep and narrow gorge and a periph‑
eral anionic site (PAS) that is surrounded by negatively 
charged and hydrophobic residues (Johnson and Moore, 
2006). Previous studies confirmed that AChE plays an 
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effective role in Aβ plaque deposition by mediating PAS 
chaperone activity (García‑Ayllón, 2011). Therefore, 
natural and synthetic compounds that effectively bind 
to the active sites, CAS and PAS, could potentially inhib‑
it ACh hydrolysis and amyloid plaque formation (Holm‑
quist, 2000; Liu et al., 2013). 
It was also previously reported that endogenous 
bile acids are potent anti‑apoptotic agents in neuronal 
cells that are exposed to Aβ (Viana et al., 2010). They 
are further known as powerful neuroprotective agents 
in various neurodegenerative diseases. Bile acids are 
structurally known as a group of antioxidants that are 
derived from cholesterol. This group can pass through 
the blood brain barrier (BBB) and was also shown to 
protect neuronal cells against oxidative damage (Lo 
et al., 2013). The neuroprotective mechanisms of bile 
acids are not completely understood but prior stud‑
ies suggest that bile acid derivatives could potentially 
block the apoptosis process through stabilization of the 
mitochondrial membrane potential (Δψm) and regula‑
tion of gene expression (Viana et al., 2010; Ackerman 
and Gerhard, 2016). Therefore, the main goal of this 
study was to evaluate the effects of cholic acid (CA) 
and sodium deoxycholate (SDC), as main bile acids, on 
the catalytic and non‑catalytic functions of AChE. The 
principal binding site of bile acids on AChE were inves‑
tigated by molecular docking analysis. Their potential 
therapeutic effects were investigated on nucleus basa‑
lis of Meynert lesioned (NBML) rats, a widely accept‑
ed model of AD that manifests pathophysiological and 
behavioral signs of the disease (Toledano and Alvarez, 
2004; Gratwicke et al., 2013). Previous results demon‑
strated that impaired memory related to AD is depen‑
dent on hippocampal function (Moodley et al., 2015; Sa‑
deghi et al., 2018). Therefore, we investigated CD and/
or SDC for beneficial effects on the NBML rats’ hippo‑
campus through biochemical analysis, immunological 
evaluation and histological studies.
METHODS
Animals
In vivo study was conducted on experimental an‑
imals by using 4.5‑6 months adult male Wistar rats, 
weighing 250‑300 g obtained from the animal house. 
All tests were carried out at 20‑25°C (12 hours light and 
12 hours dark). Municipal tap water was used as drink‑
ing water and compressed food as nutrition (consisting 
of 23% protein, 3.0% crude fat, 7.0% crude fiber: 8% acid 
insoluble ash, 1‑2.5% calcium, 0.9% phosphorus, 0.5‑1% 
sodium, 12% moisture). All the experimental works 
were approved by the Ethical Committee of Tabriz Uni‑
versity of Medical Science (Tabriz, Iran) and conform to 
the European Communities Council Directive of 24 No‑
vember 1986 (86/609/EEC).
AChE activity assessment in hippocampal  
primary culture homogenate
Primary neuronal cultures of rat hippocampus were 
prepared according to a previous study with some mod‑
ifications (Seibenhener and Wooten, 2012). Dissected 
hippocampus (isolated from neonatal rat) was triturat‑
ed by trypsin and mechanical disruption. The cells were 
differentiated in neurobasal medium supplemented 
with B27 and FGF2 for 7 days. The resulting cells were 
homogenized in cold buffer phosphate, 28 mM (pH 7.8), 
containing Triton X100 (Sadeghi et al., 2018). The ho‑
mogenized samples were then centrifuged at 13,000 g 
for 20 min and subsequent supernatants were con‑
sidered for AChE assay. AChE activity was determined 
based on spectroscopic monitoring of 5‑thio‑2‑nitro‑
benzoate anion production at 430 nm during the re‑
action between 5,5′‑Dithiobis(2‑nitrobenzoic acid) 
(DTNB) and thiocholine. In this reaction, acetylcholine 
iodide as a substrate was converted to thiocholine that 
reacts with DTNB and produces 5‑thio‑2‑nitrobenzoate. 
The final concentrations of DTNB and substrate were 
0.33 mM and 1.56 mM, respectively, in all assay medi‑
um. The activity of the enzyme was expressed as μmole 
of ACh hydrolyzed per minute per milligram protein in 
the absence and presence of bile acids (10 μM), indi‑
vidually. The homogenate’s protein concentration was 
evaluated according to the Bradford method (Bradford, 
1976). All assays were done in five replicates. 
Molecular docking analysis 
In order to precisely assess the affinity of CA and SDC to 
AChE, Auto Dock software (version 4.2) was used to simu‑
late the binding process of bile acid molecules to AChE en‑
zyme (Morris et al., 2009). For this aim, firstly, the crystal 
structure of AChE (PDB ID: 1DX6) was taken from the Pro‑
tein Data Bank (https://www.rcsb.org/). Since different 
subunits of the enzyme are the same, the subunit A was se‑
lected to perform docking analysis precisely. The 3D mo‑
lecular structures of CA and SDC were obtained from the 
PubChem website (https://pubchem.ncbi.nlm.nih.gov). 
Their structural conformations were minimized by 
Gaussian 03 programs based on a theoretical level of 
B3LYP with 6–31G basis set. Polar hydrogen atoms were 
added into AChE as a target and Kollman charges were 
also calculated. In addition, the rotation of bile acid mol‑
ecules was defined and rotatable bonds were detected. To 
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identify the ideal binding site of each bile acid on AChE 
protein, a docking calculation using the Lamarckian ge‑
netic algorithm (LGA) search method was performed. All 
other calculation parameters were default settings. Chi‑
mera 1.10.1 program was used to visualize the obtained 
results (Rizvi et al., 2013).
In vivo experimental design
NBML rats were used as an AD model as follows: rats 
were anesthetized with ketamine (125 mg/kg, i.p.) and 
xylazine (10 mg/kg, i.p) and then placed in a Stoelt‑
ing stereotaxic apparatus. The midline of clean scalp 
was notched and a burr hole was drilled into the skull. 
Following that, ibotenic acid was injected at the NBM 
nucleus with coordination as follows: AP=1.2, ML=±3.2, 
and DV=7.5 mm from the surface of skull (Paxinos and 
Watson, 2005). Each side of the NBM was injected with 
1 μl of 5 μg/μl ibotenic acid solution with a microinjec‑
tion pump at the speed of 120 μ lit/h. After 7 days of 
recovery, the animals were divided randomly into three 
groups as follows: 
Control: rats were submitted to surgery and inject‑
ed with 1 μl saline (as equivalent shock obtained by 
surgery and local injection) and were orally adminis‑
tered saline after recovery for 25 days. 
Rat model of AD: NBML rats in which both NBM nu‑
clei were bilaterally destroyed by ibotenic acid during 
surgery. These rats received saline orally after recovery 
for 25 days. 
NBML rats treated with bile acids: this group con‑
sisted of 24 rats whose NBM nuclei were bilaterally 
destroyed by ibotenic acid. After recovery, the AD‑like 
rats were randomly divided into three groups (8 rats in 
each group) and two groups were treated orally with 
30 mg/kg of SDC or CA for 25 days. The third group re‑
ceived 15 mg/kg SDC+15 mg/kg CA to study synergic 
effects of both bile acids. The dose of bile acids and the 
experimental time duration were selected according to 
a previous study (Lo et al., 2013). 
To confirm the increase of bile acid levels in the 
brain tissue of rats after 25 days of treatment (15 mg/kg 
SDC+15 mg/kg CA), the concentration of CA and SDC 
were evaluated in brain tissue by using CA and DCA 
ELISA Kit (Cell BIOLABS and MYBIOSOURCE). According 
to the obtained results, CA and DCA concentrations in 
the control group were calculated at 0.1±0.02 nmol/g 
and 0.06±0.01 nmol/g, respectively, which increased to 
0.24±0.08 nmol/g and 0.18±0.03 nmol/g, respectively, 
in rats that received combined bile acids during the 
25 days. Therefore, oral administration of bile acids 
enhanced these molecules’ concentration more than 
two‑fold in brain tissue. 
Western blotting analysis 
Western blotting was carried out according to a stan‑
dard protocol (Sadeghi et al., 2017). After SDS‑PAGE, the 
proteins were transferred onto PVDF membrane under 
140 V for 1.5‑2 h in transfer buffer. The membrane was 
probed with the primary [Anti‑Glial Fibrillary Acidic Pro‑
tein (GFAP) antibody (G3893, Sigma‑Aldrich), Anti‑beta 
Amyloid 1‑42 antibody (ab10148, Abcam), rat specific an‑
ti‑acetylcholinesterase antibody (ab31276, Abcam), rat 
specific anti‑amyloid precursor protein (APP) antibody 
(ab2072, Abcam)] and secondary specific antibodies af‑
ter blocking and washed four times in TBST (50 mM Tris, 
pH 7.5, 150 mM NaCl, 0.05 % Tween 20). An ECL detec‑
tion kit was used to visualize bands containing specific 
proteins according to the manual. Anti β‑actin (1:1000) 
(Cell Signaling Technology) was used as a housekeeping 
protein to control protein concentration. 
Histological studies 
For histological analysis, the rats from each experi‑
mental group were sacrificed under deep ketamine and 
xylazine anesthesia and before fixation with 4% form‑
aldehyde and were subsequently perfused with 0.3% so‑
dium sulphide in 0.1 M phosphate buffer. The separated 
brains were stored in 30% sucrose for cryoprotection 
and sectioned on a freezing microtome at 8 μm. The tis‑
sue sections were stained with Thioflavin T, a general 
marker of amyloid deposits, and studied by a fluores‑
cent microscope. To this purpose, the tissue sections 
were incubated with freshly filtered 0.05 % Thioflavin T 
solution in PBS for 8 min at room temperature (Batelli 
et al., 2008). 
Statistical analysis 
SPSS10 software was used to analyze the data. Anal‑
ysis and identification of the differences between ex‑
perimental groups and control were performed using 
the t‑test and p<0.05 was considered as a significant 
difference level. 
RESULTS 
Bile acids bind to the active site gorge  
and inhibit AChE catalytic activity 
AChE belongs to the serine hydrolase family that 
contains the α/β hydrolase fold as a common struc‑
tural element (Holmquist, 2000). A hallmark of AChE 
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is its catalytic activity that can be assessed by the Ell‑
man method, a sensitive, rapid and reliable method for 
detecting very low amounts of AChE catalytic function 
(Sadeghi et al., 2018). In the present study, primary 
hippocampal neuron cultures were used as a source 
of AChE to investigate the possible effects of bile ac‑
ids (CA, SDC and CA+SDC) on catalytic activity of AChE. 
The results showed that bile acids could significantly 
inhibit hydrolyzing activity of the enzyme. The cat‑
alytic function of AChE was reduced from 6.37±0.52 
to 5.56±0.31 μmol/min.mg (protein) in the presence 
of CA (10 μM), while SDC reduced AChE activity to 
3.64±0.37 μmol/min.mg (protein). Further, it was shown 
that 10 μM of combined bile acids (5 μM CA+ 5 μM SDC) 
could reduce the enzyme activity to 2.07±0.23 μmol/
min.mg (protein). The maximum rates of AChE inhibi‑
tion occurred in the presence of SDC+CA and decreased 
more than three‑fold (Table I). 
Molecular docking simulation 
Molecular docking simulation revealed that both 
of the evaluated bile acids were capable of binding to 
the active site gorge of AChE at different affinities. 
The binding energy was calculated as ‑7.76 and ‑8.94, 
respectively, for the binding of CA and SDC to the ac‑
tive site gorge. It was shown that the active site of AChE 
consists of catalytic residues (Ser 203, His 447 and Glu 
334), which are located within the gorge, similar to 
other AChEs in mammals (Johnson and Moore, 2006; 
García‑Ayllón et al., 2011; Liu et al., 2017). Also, some 
anionic and hydrophobic amino acids surround the en‑
trance of the active site known as the PAS site (Tyr 286, 
Trp 286, Phe 338, Val 294 and Leu 289) (Johnson and 
Moore, 2006; García‑Ayllón et al., 2011). Fig. 1 shows the 
binding sites of bile acids on the active site of AChE. It 
was indicated that CA due to the bulky structure could 
bind to PAS and is not able to reach to the catalytic site 
at deep of the gorge so could limit substrate access to 
the catalytic site. While SDC could pass through the PAS 
tunnel and reach to CAS which limits substrate binding 
to the active site. All docking results are listed in Table I. 
Bile acids treatment attenuated catalytic  
activity of hippocampal AChE that was  
increased by NBM lesion 
NBM lesion causes impaired spatial navigation 
according to Fig. S1 (supplementary data) in exper‑
imental animals. The pathogenesis of AD has been 
linked to AChE activation that is also accompanied 
by β‑amyloid deposition (Dong et al., 2004; Johnson 
and Moore, 2006). Therefore, to investigate wheth‑
er NBM lesion and oral administration of bile acids 
could affect AChE activity in the rat hippocampus, 
the enzyme activity in homogenate tissue was eval‑
uated for all groups. In agreement with our previous 
study (Sadeghi et al., 2013), the results showed that 
AChE activity was significantly increased in NBML 
rats up to 2982.71±152.26 nmol/min.mg protein, while 
the enzyme activity in the control hippocampus was 
calculated to be 525.34±34.52 nmol/min.mg protein 
(Fig. 2). NBML rats that treated with 30 mg/kg of SDC 
and/or CA for 25 days, showed reduced AChE activity 
compared with the NBML rats that treated with saline. 
Fig. 2 shows that the activity of AChE was remarkably 
reduced (3‑fold) in NBM lesioned rats were adminis‑
tered 30 mg/kg of SDC. NBML rats received 30 mg/kg 
of CA revealed a two‑fold reduction in AChE activity in 
hippocampal tissue. The enzyme activity was, howev‑
er, remarkably inhibited in the rats that received both 
of the bile acids (520.13±50.25 nmol/min.mg protein), 
indicating synergistic effects. 
Bile acids improved abnormal expression  
of GFAP, Aβ and AChE 
Western blot analysis confirmed the increased ex‑
pression of GFAP, a well‑known biomarker for neuronal 
Table I. The effects of bile acids on hydrolytic activity of AChE and binding parameters of each bile acid on the enzyme. Experimental data was expressed 
as the mean ± S.E.M. of at least five independent tests.
Bile acids AChE activity (μmol/min.mg protein)
Binding energy 
(kcal/mol) Interacting amino acids
Control 6.37±0.52 – –
Cholic acid (CA) 5.56±0.3 ‑7.76 Ser 293, Arg 296, Tyr 124, Tyr 341, Val 294, Leu 289,  Trp 286, Phe 297, Tyr 337, Phe 338
Sodium deoxycholate (SDC) 3.64±0.37 ‑8.94 Tyr 133, Asn 87, Pro 88, Glu 202, Trp 86, Tyr 124, Tyr 337 and His 447
CA+SDC 2.07±0.23 – –
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damage in ibotenic acid received hippocampus (Lei et 
al., 2015). In this study, it was revealed that the GFAP 
content of hippocampal tissue was reduced in the rats 
treated with bile acids, especially the rats that received 
CA+SDC daily. Our results also revealed that AChE ex‑
pression was enhanced in hippocampal tissue of NBML 
rats, while bile acids significantly reduced its expres‑
sion. Fig. 3 reveals that the effects of CA and the com‑
bination of both bile acids are more significant than 
SDC treatment. According to the results, the level of Aβ 
content was six‑fold in the NBML rats compared with 
the control. Interestingly, CA caused a greater decrease 
in the level of Aβ in hippocampal cells (more than 
five‑fold) than SDC (near to two‑fold). Our results also 
confirmed nonlinear cumulative effects of CA and SDC 
in the reduction of AChE expression.
Bile acids improved histopathological 
abnormalities induced by NBM lesion 
In this investigation, histological studies were done 
as confirmation of biochemical results. Thioflavin 
staining demonstrated a clear abundance of amyloid 
plaques in the hippocampal tissue of NBML rats; how‑
ever, deposits were absent in the control rats. In agree‑
ment with a previous study (Lo et al., 2013), thioflavin 
plaque numbers were reduced in the hippocampus of 
bile acids‑supplemented‑NBML rat compared to the 
NBML rats that treated with saline. Thioflavin plaque 
Fig. 1. Bile acid molecules in the AChE active site gorge. (A) shows the surface view of the active site cavity representing the crystal structure of AChE with 
two bile acids bound. (B) shows a cartoon form of one subunit of AChE that binds to bile acids by hydrophobic interactions and hydrogen bonds. CA and 
SDC are represented as a cyan and brown molecule, respectively. (C) indicates the binding position of each bile acid in the active site gorge in comparison 
with PAS and CAS sites. (D) shows molecular structures of each bile acid with the C7 marked in red. 
Fig. 2. AChE activity in the hippocampus tissue. Results showed a signifi‑
cant increase in hydrolyzing activity in NBML rat’s hippocampus that was 
attenuated with bile acids treatment. Co‑administration of CA and SDC 
was most significant. The data were expressed as mean ± S.E.M. of five 
independent experiments and an asterisk (*) symbol indicates significant 
changes in comparison with NBML rats (p<0.05).
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numbers significantly decreased in the groups treated 
with SDC and CA. Fig. 4 also shows cumulative effects 
of both bile acids in AD rats that received SDC and CA 
simultaneously and resulted to decreased number and 
size of plaques. 
DISCUSSION 
We investigated the effects of bile acids (SDC and 
CA) on hippocampal AChE activity as an important 
target in AD therapy. The in vitro investigation of AChE 
was carried out using Ellman’s method with crude 
enzyme that was extracted from primary neuronal 
cultures approximating neonatal rat hippocampus 
(Sadeghi et al., 2018). The results showed that both 
bile acids could significantly inhibit AChE hydrolytic 
activity (Table I) possibly due to substrate accessibil‑
ity restriction. AChE protein possesses two sites for 
ligand interactions: an active (hydrolytic) site within 
a deep narrow gorge (CAS), including Ser203, Glu334 
and His447, and a peripheral anionic site (PAS) that 
consists of a group of negatively charged and hydro‑
phobic residues surrounding the entrance site (Prash‑
er, 2004; Liu et al., 2017). The CAS is located within the 
inner site of the enzyme and substrate molecules must 
pass through the PAS tunnel to reach to the CAS, the 
distance between the two position estimated to be ap‑
proximately 12 Å. Molecular docking studies revealed 
that SDC, upon binding to the CAS, could inhibit es‑
terase activity more significantly; however, since CA 
could not reach to the catalytic site within the gorge, 
it could not effectively inhibit hydrolytic activity but 
could possibly limit substrate access by binding to the 
PAS site. Structural and docking analysis of bile acids 
revealed that the presence of hydroxyl group at C7 of 
the sterol rings limited bile acid from penetrating to 
the active site gorge possibly due to the increasing 
molecular dimensions that lead to decreased flexibili‑
ty. Interestingly, AChE activity decreased more signifi‑
cantly in the presence of an equivalent combination 
of CA and SDC, which suggests synergistic inhibitory 
effects. Regarding the different physiological roles of 
PAS and CAS in biological systems, the effects of CA 
(binds to PAS), SDC (binds to CAS) and CA+SDC (bind 
to PAS and CAS) on biochemical and molecular aspects 
of AD were investigated by using NBML rats, a recog‑
nized animal model of AD. 
Local injection of ibotenic acid damaged acetyl‑
choline manufacturing cells in the NBM and caused 
AChE hyper‑activation in hippocampus that ultimate‑
ly led to AD pathophysiological signs (Wenk, 1990; 
Anand and Singh, 2013). According to the results, oral 
administration of bile acids for 25 days enhanced CA 
and DCA concentrations in the brain tissue more than 
two‑fold. Therefore, similar to the in vitro assay, oral 
administration of SDC and CA effectively decreased 
the activity of hippocampal AChE. NBML rats that re‑
ceived both of bile acids in similar doses (15 mg/kg 
CA+15 mg/kg SDC) exhibited minimal hippocampal 
AChE hydrolytic activity (near control values), which 
indicates non‑linear cumulative effects similar to the 
in vitro results. Immunoblotting analysis also con‑
firmed enhanced AChE expression, due to NBM lesion, 
Fig. 3. Immunoblotting studies. Results showed upregulation of AChE, Aβ and GFAP proteins in NBML rats that can be interpreted as hippocampal damage, 
which improved with oral administration of bile acids. (A) Lane 1 represents control hippocampus, lane 2 shows results in NBML rats. Lane 3 represents 
SDC‑treated NBML rats, lane 4 represents NBML rats treated with CA and lane 5 shows results in NBML rats that received CA+SDC. (B) Immunoblotting 
results quantified with Image J software as a plot. The data were expressed as mean ± S.E.M. of at least three independent experiments and asterisk (*) 
symbol indicates significant changes in comparison with NBML rats (p<0.05).
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decreased significantly with bile acids treatment, es‑
pecially in rats that received CA and CA+SDC. NBM 
lesion caused an approximately 4‑fold increase in 
AChE expression but its activity increased more than 
5.6‑fold. Therefore, activation and increased expres‑
sion of AChE were taking place simultaneously. Pre‑
vious experiments indicate that bile acids could reg‑
ulate gene expression through binding to the G‑pro‑
tein‑coupled bile acid membrane receptor 1 (TGR5) 
and bile acid nuclear Farnesoid X receptor (FXR) at 
the membrane and inside the nucleus, respectively 
(Mertens et al., 2017). SDC treatment reduced AChE 
expression slightly but decreased its catalytic activity 
more than 4‑fold. The reduction of AChE expression 
and catalytic activity in the presence of CA seems to 
be equal; therefore, it appears that CA reduces AChE’s 
hydrolyzing activity primarily through regulation of 
gene expression. Therefore, these results reveal that 
the expression and activity of AChE enzyme could be 
regulated by different pathways. 
Fig. 4. Thioflavin staining of hippocampus tissue. Results showed absence of amyloid plaques in control rats. Hippocampal sections representing NBML 
rats showed high amounts of deposited amyloids. Amyloid deposit amounts were reduced in rats that received the PAS‑interacting bile acid (CA) versus 
SDC, which could not bind to the PAS.
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AChE is colocalized with Aβ in pre‑amyloid depos‑
its, mature senile plaques and cerebral blood vessels in 
the brain of AD patients, which suggests its role in pro‑
motion and development of Aβ plaques (Inestrosa et 
al., 1996). In vitro and in silico analyses confirmed that 
Aβ has a marked tendency to interact with the PAS site 
mainly via hydrophobic interactions (García‑Ayllón 
et al., 2011). The increased activity and expression of 
AChE in NBML rats suggests that the chaperone role of 
AChE also improved, which is associated with the PAS 
site and is responsible for Aβ polymerization. Inter‑
estingly, it was observed that CA binds to the PAS site 
and reduces amyloid plaques more significantly than 
SDC, which mainly interacts with CAS. It is possible 
that CA could have bound to PAS, inhibited the chap‑
erone function of AChE and attenuated Aβ plaques 
deposition, leading to the decrease of plaque number 
and size. NBM lesion by ibotenic acid caused choliner‑
gic system impairment and led to the increased GFAP 
content in hippocampal cells that confirmed AD is 
a neurodegenerative disease (Moodley et al., 2015; Lei 
et al., 2015). The treatment of rats with CA or CA+SDC 
resulted in a strong decrease in neuronal damage com‑
pared to rats that received SDC. Simultaneous AChE 
upregulation and increased expression of Aβ and GFAP 
suggests a possible role for AChE in the regulation of 
the genes involved in apoptosis as a non‑catalytic 
function (Dong et al., 2004). The effect of bile acids at 
the molecular level resulted in the refinement of be‑
havioral abnormalities caused by NBM lesion in rats. 
Fig. S1 reveals that NBML rats treated with CA+SDC for 
25 days took less time to reach the platform than rats 
that received normal saline, SDC or CA. 
Overall, this is an original report of the bile acids’ 
therapeutic effects on NBM lesion‑induced patholo‑
gy through in vivo, in vitro and in silico experiments, 
which results suggests a novel approach in AD ther‑
apy. Our results confirmed that SDC more strongly 
inhibited hydrolytic functions, possibly by binding 
to the catalytic site, while CA binds to the PAS site 
and inhibited non‑catalytic functions of AChE such 
as plaque formation and gene regulation. Therefore, 
in the presence of both bile acids, CAS and PAS were 
inhibited simultaneously and both of the catalytic 
and non‑catalytic functions were attenuated, result‑
ing in the inhibition of ACh hydrolysis and reducing 
size and number of plaques. Thus, this study suggests 
AChE regulation is an essential role for bile acids as 
liver‑derived molecules in the CNS. Considering the 
similarity between the NBML model and AD at mo‑
lecular and physiological levels, CA and SDC may be 
potential therapeutic adjuvants for patients that are 
suffering from AD or other related cognitive disor‑
ders. This study additionally provides new structural 
information for the rational design of new inhibitors 
against AChE. 
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SUPPLEMENTAL MATERIAL
Fig. S1. Spatial learning evaluation by the Morris water maze test. The 
rats’ latency to reach the platform increased in NBML rats in comparison 
with control on 3 consecutive test days. 30 mg/kg of bile acids decreased 
latency time for AD rats to reach the platform. Treatment with CA+SDC 
improved spatial navigation in NBML rats more significantly in comparison 
with other groups. Each data point indicates the mean ± S.E.M. The 
asterisks (*) indicate significant differences (p<0.05) according to Duncan’s 
multiple range test.
